<DOC>
	<DOC>NCT00316433</DOC>
	<brief_summary>The purpose of this study is to determine the safety and effectiveness of the combination of oxaliplatin and irinotecan (CPT-11) in patients with previously untreated, advanced small cell lung cancer.</brief_summary>
	<brief_title>Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Previously untreated extensive small cell lung cancer No prior chemotherapy No prior radiotherapy except for the treatment of brain metastases Prior treatment for extensive stage small cell lung cancer Known hypersensitivity to any of the components of oxaliplatin or CPT11 Greater than grade 2 peripheral neuropathy Known HIV or Hepatitis B or C (active, previously treated or both)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>